Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04134845 · ClinicalTrials.gov registry record · Phase 2

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

A Phase 2 study of Ventricular Tachycardia, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
Phase 2
Development phase
68
Enrollment target
1
Study location

NCT04134845: Completed Phase 2 study of Ventricular Tachycardia, sponsored by Vanderbilt University Medical Center.

NCT04134845 is a Phase 2 study of Ventricular Tachycardia that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 68 participants, below the 286-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04134845, a Phase 2 study of Ventricular Tachycardia, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, placebo-controlled trial of Dantrolene (N= 84 participants) to demonstrate the feasibility of using intravenous (IV) dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics, and ventricular arrhythmia inducibility in patients with structural heart disease referred for Ventricular Tachycardia (VT) ablation. The investigators will also explore the pharmacokinetic/pharmacodynamic relationship of IV dantrolene and its short-term effect on specific cardiac electrophysiologic and hemodynamic parameters.

Primary Outcome

Post drug ventricular stimulation with Right Ventricle (RV) ventricular catheter in the Right Ventricle( RV) apex with increasing extra stimuli with planned decrement stimuli by 10 milliseconds (ms) to effective refractory period (ERP). Outcome is measured as Ventricular inducibility yes/no.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Dantrolene/Ryanodex

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2020-08-21
Est. Completion 2025-08-29
Phase Phase 2

What the finished NCT04134845 record still lists

NCT04134845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 286-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04134845 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT04134845 about?

NCT04134845 is a clinical study titled "A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.". This is a randomized, placebo-controlled trial of Dantrolene (N= 84 participants) to demonstrate the feasibility of using intravenous (IV) dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics, and ventricular arrhythmia inducibility in patients with structural...

What is the current status of trial NCT04134845?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2020-08-21. Estimated completion is 2025-08-29.

What conditions does trial NCT04134845 study?

This clinical trial studies the following conditions: Ventricular Tachycardia.

What interventions are being tested in trial NCT04134845?

The interventions under investigation include: Placebo (DRUG), Dantrolene/Ryanodex (DRUG).

Who is sponsoring clinical trial NCT04134845?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04134845 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ventricular Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04134845's enrollment target sits among peer trials

68 18th of 28 higher than 11 of 28 other Ventricular Tachycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ventricular Tachycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04134845, the US trial registry maintained by the National Library of Medicine. NCT04134845 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.